NatureReal-world eligibility, utilization, and barriers to CAR T-cell therapy in relapsed/refractory mantle cell lymphomaPrior to the advent of chimeric antigen receptor (CAR) T-cell therapy, patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL)….6 hours ago